FK506 promotes adenosine release from endothelial cells via inhibition of adenosine kinase

European Journal of Pharmacology

Volumn 425, Issue 2, 2001, Pages 85-93

  Hwang, Kwan Ki ^a   Hall, Carolyn S ^a   Spielman, William S ^a   Sparks, Harvey V ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Adenosine; Adenosine kinase; Endothelial cell; FK506

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 AMINO 3 BROMOPYRAZOLO[3,4 D]PYRIMIDINE 1 (5 AMINO 5 DEOXYRIBOSIDE); ADENOSINE; ADENOSINE KINASE; ADENOSINE KINASE INHIBITOR; CALCINEURIN INHIBITOR; CYCLOSPORIN A; GENISTEIN; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TACROLIMUS; WORTMANNIN;

AMINO ACID BLOOD LEVEL; AMINO ACID TRANSPORT; ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HEART INFARCTION PREVENTION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION;

ADENOSINE; ADENOSINE KINASE; ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; ENDOTHELIUM; ENZYME INHIBITORS; MITOGEN-ACTIVATED PROTEIN KINASES; RATS; SIROLIMUS; TACROLIMUS;

EID: 0035839171     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)01179-7     Document Type: Article

References (42)

1. Purification and properties of human placental adenosine kinase
2. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance
3. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin
4. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury
5. Adenine nucleotide release from isolated perfused guinea pig hearts and extracellular formation of adenosine
6. Adenosine inhibits neutrophil degranulation in activated human whole blood: Involvement of adenosine A2 and A3 receptors
7. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: Established and putative beneficial actions of a retaliatory metabolite
8. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine
9. Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB
10. Sites of action for future therapy: An adenosine-dependent mechanism by which aspirin retains its antiinflammatory activity in cyclooxygenase-2 and NFkappaB knockout mice
11. 2-Fluoroadenosine uptake by erythrocytes and endothelial cells studied by 19F-NMR
12. Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release
13. Effects of phorbol esters and secretagogues on nitrobenzylthioinosine binding to nucleoside transporters and nucleoside uptake in cultured chromaffin cells
14. Contribution of coronary endothelial cells to cardiac adenosine production
15. Formation and salvage of adenosine by macrovascular endothelial cells
16. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury
17. Protective effect of an adenosine kinase inhibitor in septic shock
18. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia
19. Inorganic phosphate as regulator of adenosine formation in isolated guinea pig hearts
20. Characterization of inhibitor-sensitive and -resistant adenosine transporters in cultured human fetal astrocytes
21. Interactions between cyclosporine A and adenosine in kidney transplant recipients
22. Cardioprotective effects of the calcineurin inhibitor FK506 and the PAF receptor antagonist and free radical scavenger, EGb 761, in isolated ischemic/reperfused rat hearts
23. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs
24. Adenosine kinase inhibitors
25. Release of adenosine and cyclic AMP from coronary endothelium in isolated guinea pig hearts: Relation to coronary flow
26. Tumour necrosis factor stimulates stress-activated protein kinases and the inhibition of DNA synthesis in cultures of bovine aortic endothelial cells
27. Cardioprotection by cyclosporine A in experimental ischemia and reperfusion - Evidence for a nitric oxide-dependent mechanism mediated by endothelin
28. Mechanisms of action of cyclosporine
29. Protection of the myocardium by ischaemic preconditioning: Mechanisms and therapeutic implications
30. Harnessing an endogenous cardioprotective mechanism: Cellular sources and sites of action of adenosine
31. How does dipyridamole elevate extracellular adenosine concentration? Predictions from a three-compartment model of adenosine formation and inactivation
32. Anti-inflamatory effects of an adenosine kinase inhibitor. Decreased neutrophil accumulation and vascular leakage
33. Release of adenosine from pig aortic endothelial cells during hypoxia and metabolic inhibition
34. Endothelial nucleotide catabolism and adenosine production
35. Adenosine transport in cultured human umbilical vein endothelial cells is reduced in diabetes
36. Adenosine release of the isolated guinea pig heart is regulated by phosphorylation of adenosine kinase
37. Cyclosporin A and FK506 inhibit adenosine uptake and adenosine kinase activity in T-lymphocytes
38. Adenosine metabolism during phorbol myristate acetate-mediated induction of HL-60 cell differentiation: Changes in expression pattern of adenosine kinase, adenosine deaminase, and 5′-nucleotidase
39. Activation of Raf as a result of recruitment to the plasma membrane
40. Adenosine transporters
41. Neuroprotective FK506 does not alter in vivo nitric oxide production during ischemia and early reperfusion in rats
42. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia